Peter Dijk

Peter Dijk is a Professor at the University Medical Center Groningen, University of Groningen, specializing in neonatology and perinatal medicine. His research focuses on improving outcomes for preterm and critically ill newborns through pharmacokinetic studies, therapeutic hypothermia applications, and assessment of clinical stressors in NICU settings.

His research interests span several critical areas in neonatal care:

• Pharmacokinetics of medications in neonates, particularly for infants undergoing therapeutic hypothermia
• Management of perinatal asphyxia and its complications
• Development and validation of risk prediction models for conditions like retinopathy of prematurity
• Assessment of clinical stressors during NICU admission and their impact on preterm infant development

Dr. Dijk's recent publications (2023-2025) demonstrate a strong focus on optimizing drug therapy for vulnerable newborn populations, with particular attention to vancomycin and gentamicin pharmacokinetics in infants receiving therapeutic hypothermia. His work on the HIPPO study examines stress exposure in preterm infants, while his international collaboration on retinopathy of prematurity has produced a risk scoring model specifically designed for Indonesian healthcare settings.

His research contributions support several UN Sustainable Development Goals related to good health and well-being, particularly through improving neonatal survival and health outcomes.

Dr. Dijk maintains active collaborations through the HIPPO study group and PharmaCool Study Group, working with multiple institutions across the Netherlands and internationally. His research program addresses critical gaps in neonatal pharmacology and care practices, with direct implications for clinical protocols in neonatal intensive care units worldwide.